Clinical Trial Update: A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated safety, tolerability and immune response to ASP0892 (ARA-LAMP-vax), a multivalent DNA plasmid vaccine targeting peanut allergens Ara h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• ASP0892 (ARA-LAMP-vax)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Peanut Allergy | Phase 1 | Status: COMPLETED